Article

Yoo YG, Kong G, Lee MO.. Metastasis-associated protein 1 enhances stability of hypoxia-inducible factor-1alpha protein by recruiting histone deacetylase 1. EMBO J 25: 1231-1241

Hanyang University, Sŏul, Seoul, South Korea
The EMBO Journal (Impact Factor: 10.43). 04/2006; 25(6):1231-41. DOI: 10.1038/sj.emboj.7601025
Source: PubMed

ABSTRACT

The expression of metastasis-associated protein 1 (MTA1) correlates well with tumor metastases; however, the associated molecular mechanism is not fully understood. Here, we explored the possibility of cross-talk between MTA1 and hypoxia-inducible factor-1alpha (HIF-1alpha), a key regulator of angiogenic factors. We observed that the expression of MTA1 was strongly induced under hypoxia in breast cancer cell lines such as MCF-7 and MDA-MB-231. When MTA1 was overexpressed, the transcriptional activity and stability of HIF-1alpha protein were enhanced. MTA1 and HIF-1alpha are physically associated in vivo and they were localized completely in the nucleus when coexpressed. MTA1 induced the deacetylation of HIF-1alpha by increasing the expression of histone deacetylase 1 (HDAC1). MTA1 counteracted to the action of acetyltransferase, ARD1, and it did not stabilize the HIF-1alpha mutant that lacks the acetylation site, K532R. These results indicate that acetylation is the major target of MTA1/HDAC1 function. Collectively, our data provide evidence of a positive cross-talk between HIF-1alpha and MTA1, which is mediated by HDAC1 recruitment, and indicate a close connection between MTA1-associated metastasis and HIF-1-induced tumor angiogenesis.

Download full-text

Full-text

Available from: Mi-Ock Lee, Nov 24, 2014
  • Source
    • "Protein SSAT2 stabilizes the union between VHL-E3 ubiquitin ligase complex and HIF-1í µí»¼ promoting HIF-1í µí»¼ degradation [40]. HIF-1í µí»¼ can be acetylated in the Lys532 by ARD1 for its subsequent degradation via VHL [41], but the " metastasis-associated protein 1 " (MTA1) can counteract the activity of ARD1 [42]. " VHL-interacting deubiquitinating enzyme 2 " (VDU2) is another protein that stabilizes HIF-1í µí»¼, because it deubiquitinates HIF-1í µí»¼ avoiding its degradation [43] [44]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Psoriasis is a chronic inflammatory skin disease where the altered regulation in angiogenesis, inflammation, and proliferation of keratinocytes are the possible causes of the disease, and the transcription factor "hypoxia-inducible factor 1-alpha" (HIF-1 alpha) is involved in the homeostasis of these three biological phenomena. In this review, the role of HIF-1 alpha in the cross talk between the cytokines and cells of the immunological system involved in the pathogenesis of psoriasis is discussed.
    Full-text · Article · Jul 2015 · Mediators of Inflammation
  • Source
    • "As transcriptional cofactors, several histone modifying enzymes have been reported to regulate HIF-1 transactivation. The histone acetyltransferase p300 and histone deacytylases (HDACs) regulate HIF-1 transcriptional activity by acetylation/deacetylation [17] [18] [19] [20] [21] [22]. The histone methyltransferase G9a and histone demethylase jumonji domain containing protein 1A (JMJD1A) and JMJD2C regulate HIF-1 transactivation through methylation/demethylation of histone and non-histone proteins [23] [24] [25]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: HIF-1α is degraded by oxygen-dependent mechanisms but stabilized in hypoxia to form transcriptional complex HIF-1, which transactivates genes promoting cancer hallmarks. However, how HIF-1α is specifically regulated in hypoxia is poorly understood. Here, we report that the histone methyltransferase SET9 promotes HIF-1α protein stability in hypoxia and enhances HIF-1 mediated glycolytic gene transcription, thereby playing an important role in mediating cancer cell adaptation and survival to hypoxic stress. Specifically, SET9 interacts with HIF-1α and promotes HIF-1α protein stability in hypoxia. Silencing SET9 by siRNA reduces HIF-1α protein stability in hypoxia, and attenuates the hypoxic induction of HIF-1 target genes mediating hypoxic glycolysis. Mechanistically, we find that SET9 is enriched at the hypoxia response elements (HRE) within promoters of the HIF-1-responsive glycolytic genes. Silencing SET9 reduces HIF-1α levels at these HREs in hypoxia, thereby attenuating HIF-1-mediated gene transcription. Further, silencing SET9 by siRNA reduces hypoxia-induced glycolysis and inhibits cell viability of hypoxic cancer cells. Our findings suggest that SET9 enriches at HRE sites of HIF-1 responsive glycolytic genes and stabilizes HIF-1α at these sites in hypoxia, thus establishes an epigenetic mechanism of the metabolic adaptation in hypoxic cancer cells.
    Full-text · Article · Jan 2015 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
  • Source
    • "The binding of E7 to HIF-1α was directly inhibited through deletion of the N-terminus pRb binding domain of E7. Many HDACs (including HDAC1, 4, and 7) enhance HIF-1 activity on their own (Kato et al., 2004; Qian et al., 2006; Yoo et al., 2006), however the authors hypothesized that binding of HPV E7 to HIF-1α allows for the displacement of these HDAC's from HIF-1α, permitting formation of the HIF-1 transcription complex, leading to downstream activation of target genes. Previously, under conditions mimicking hypoxia, cells treated with the hypoxic mimetic, deferoxamine, plus high-risk HPV E7 or E6 exhibited higher protein levels of HIF-1α in comparison to non-transduced keratinocytes under the same conditions (Nakamura et al., 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The advent of modern molecular biology has allowed for the discovery of several mechanisms by which oncoviruses promote carcinogenesis. Remarkably, nearly all human oncogenic viruses increase levels of the transcription factor hypoxia-inducible factor 1 (HIF-1). In this review, we highlight HIF-1׳s significance in viral oncogenesis, while providing an in-depth analysis of its activation mechanisms by the following oncoviruses: human papillomaviruses (HPVs), hepatitis B/C viruses (HBV/HCVs), Epstein-Barr virus (EBV), Kaposi׳s sarcoma-associated herpes virus (KSHV), and human T-cell lymphotropic virus (HTLV-1). We discuss virus-induced HIF-1׳s role in transcriptional upregulation of metabolic, angiogenic, and microenvironmental factors that are integral for oncogenesis. Admittedly, conclusive evidence is lacking as to whether activation of HIF-1 target genes is necessary for malignant transformation or merely a result thereof. In addition, a complete understanding of host-virus interactions, the effect of viral genomic variation, and the clinical (and potential therapeutic) relevance of HIF-1 in viral oncogenesis warrant further investigation.
    Full-text · Article · Mar 2014 · Virology
Show more